Genesis nets $200M for AI drug design

Today’s Big News

Aug 21, 2023

KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras


Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet


AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing


Fierce Biotech analysis: 2023 biopharma layoffs now match 2022’s total


Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown: Evaluate


Bruker taps into single-cell biology with $108M deal for PhenomeX

 

Featured

KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras

The FDA will hold an advisory committee meeting to discuss confirmatory trial data for Amgen's Lumakras in KRAS-mutated lung cancer. This comes after a bumpy stretch for the medicine since its debut in 2021.
11-14
Sep
Philadelphia, PA
 

Top Stories

Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet

Exactly a month after Gilead revealed it had shelved a myelodysplastic syndromes program for magrolimab, the molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia studies.

AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing

First spun out of Stanford University in late 2019, the company's deep learning platform helps design small-molecule drug compounds and predicts how they interact with the body.

Fierce Biotech analysis: 2023 biopharma layoffs now match 2022’s total

Layoffs in the biotech industry for 2023 have matched the total number of companies that cut staff in all of 2022, with 119 biopharmas reporting workforce reductions so far this year, according to an analysis of Fierce Biotech data. 

Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown: Evaluate

Merck cancer superstar Keytruda is projected to be the world’s top selling drug by a huge margin in 2028, according to a report by Evaluate. On its list of top 10 drugs by sales in 2028, Keytruda is expected to top the $30 billion mark, with no other therapy predicted to reach $20 billion in sales.

Bruker taps into single-cell biology with $108M deal for PhenomeX

PhenomeX was formed earlier this year after Berkeley Lights bought up IsoPlexis, a former Fierce Medtech Fierce 15 winner.

Moderna reveals Claudin18.2 ambitions via cancer vaccine, solid tumor CAR-T combo plans

What could be hotter than Moderna getting in the Claudin18.2 race? How about pairing up this mRNA therapeutic cancer vaccine with a solid tumor-targeting CAR-T?

ICU Medical to lay off 82 workers, wind down operations at Minnesota facility

ICU Medical plans to lay off several dozen workers in the process of permanently shutting down a manufacturing facility in Minnesota.

After Regeneron scores FDA nod for high-dose Eylea, it’s game on in showdown with Roche’s Vabysmo

With the FDA signing off on Regeneron and Bayer’s high-dose Eylea, the companies are set to take on Roche’s Vabysmo in a high-stakes battle for the massive eye disease market.

BARDA backs Satio’s development of a patch-based Ebola test

Satio is building rapid, patch-based devices to collect both dried blood spots and whole blood samples, which are now set to be combined with an Ebola diagnostic from Senegal’s Institut Pasteur de Dakar to create an all-in-one blood collecting and testing platform for the virus.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': Trends at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage
 

Resources

Whitepaper

Plan for success with your process liquid and buffer preparation

Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity.
Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.
Research

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.
 
 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events